EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cystathionine as a Potential Urinary Marker for Diagnosing and Assessing Pretreatment Risk in Neuroblastoma

Hizuru Amano iD, Yoshiharu Hayashi, Kazuharu Harada, Atsushi Narita, Shigehisa Fumino, Yuji Yamada, Shuhei Karakawa, Minoru Sakairi, Chiyoe Shirota, Takahisa Tainaka, Kazuki Yokota, Satoshi Makita und 15 weitere

Cancer Science · 2025

DOI: 10.1111/cas.70169 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Hizuru Amano und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan. Hauptthemen laut MEDLINE: Neuroblastoma, Biomarkers, Tumor, Cystathionine. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Urinary homovanillic acid (HVA) and vanillylmandelic acid (VMA) are widely used diagnostic markers for neuroblastoma, but urinary markers for risk assessment prior to invasive biopsy are lacking. We hypothesized that cystathionine (CTN) may be a new neuroblastoma biomarker and evaluated its utility for diagnosis and pretreatment risk assessment. 80 participants provided 202 urine samples: 32 from 32 control participants, 29 from 29 patients with primary neuroblastoma, and 141 from 30 patients with residual tumors, 11 of whom had primary neuroblastoma. Urinary CTN and HVA/VMA concentrations were measured using liquid chromatography/mass spectrometry. The area under the receiver operating characteristic curve (ROC‐AUC) was used to evaluate diagnostic and pretreatment risk assessment performance according to the International Neuroblastoma Risk Group (INRG) pretreatment risk classification and the revised 2021 Children's Oncology Group (COG) neuroblastoma risk classification. Associations with prognostic factors were also evaluated. The AUC values for diagnosis were 0.920, 0.903, and 0.946 for HVA, VMA, and CTN, respectively. For pretreatment risk assessment (high‐risk versus intermediate‐ and low‐risk, and high‐ and intermediate‐risk versus low‐risk) the AUCs according to the INRG classification were 0.576 and 0.578 for HVA, 0.524 and 0.513 for VMA, and 0.852 and 0.708 for CTN, respectively, whereas they were 0.530 and 0.741 for HVA, 0.510 and 0.796 for VMA, and 0.758 and 0.981 for CTN, respectively, according to the COG classification. The values for MYCN status were 0.844 for HVA, 0.844 for VMA, and 0.942 for CTN. CTN may be a useful urinary marker for neuroblastoma diagnosis and pretreatment risk assessment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaBiomarkers, TumorCystathionineHumansMaleFemaleChild, PreschoolInfantChildPrognosisRisk AssessmentVanilmandelic AcidROC CurveHomovanillic AcidCase-Control StudiesAdolescent

Stichwörter der Autor:innen

biomarkercystathionineneuroblastoma

Substanzen

Biomarkers, TumorCystathionineVanilmandelic AcidHomovanillic Acid

Autor:innen und Institutionen

  • Department of Pediatric Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Bioanalysis Research Department, CMIC Pharma Science co., Ltd., Hyogo, Japan.
  • Department of Health Data Science, Tokyo Medical University, Tokyo, Japan.
  • Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Department of Pediatric Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.

ORCID-Profile: Hizuru Amano

Förderung

  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development

Zitieren

APA

Amano, H., Hayashi, Y., Harada, K., Narita, A., Fumino, S., Yamada, Y., Karakawa, S., Sakairi, M., Shirota, C., Tainaka, T., Yokota, K., Makita, S., Kato, D., Ishii, H., Deie, K., Mori, M., Mitani, Y., Tomioka, Y., Taguri, M., …, & Uchida, H. (2025). Cystathionine as a Potential Urinary Marker for Diagnosing and Assessing Pretreatment Risk in Neuroblastoma. Cancer Science. https://doi.org/10.1111/cas.70169

Vancouver

Amano H, Hayashi Y, Harada K, Narita A, Fumino S, Yamada Y, et al. Cystathionine as a Potential Urinary Marker for Diagnosing and Assessing Pretreatment Risk in Neuroblastoma. Cancer Science. 2025. doi:10.1111/cas.70169

BibTeX
@article{Amano2025,
  author = {Amano, Hizuru and Hayashi, Yoshiharu and Harada, Kazuharu and Narita, Atsushi and Fumino, Shigehisa and Yamada, Yuji and Karakawa, Shuhei and Sakairi, Minoru and Shirota, Chiyoe and Tainaka, Takahisa and Yokota, Kazuki and Makita, Satoshi and Kato, Daiki and Ishii, Hiroki and Deie, Kyoichi and Mori, Makiko and Mitani, Yuichi and Tomioka, Yutaka and Taguri, Masataka and Koh, Katsuyoshi and Tajiri, Tatsuro and Kato, Motohiro and Matsumoto, Kimikazu and Takahashi, Yoshiyuki and Iehara, Tomoko and Hinoki, Akinari and Uchida, Hiroo},
  title = {Cystathionine as a Potential Urinary Marker for Diagnosing and Assessing Pretreatment Risk in Neuroblastoma},
  journal = {Cancer Science},
  year = {2025},
  doi = {10.1111/cas.70169}
}
Kostenlos starten →